TGR-1202, a next generation PI3K-delta inhibitor in CLL and B-cell lymphomas

Owen A O’Connor, MD, PhD from the Columbia University Medical Center Center for Lymphoid Malignancies, New York, NY, talks about a study on TGR-1202 presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. TGR-1202 is a novel, next generation PI3K-delta inhibitor, found to show a favorable safety and tolerability profile and promising activity in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.